Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
No Data Available.
Synonyms :
minocycline
Class :
Tetracyclines
Dosage Forms & Strengths  Â
Tablet or Capsule  Â
50mg  Â
75mg  Â
100mg  Â
Tablet- extended release  Â
45mg   Â
55mg   Â
65mg   Â
80mg   Â
90mg   Â
105mg   Â
135mg   Â
initial dose:
200
mg
Intravenous (IV)
followed by 100 mg IV for every 12hrs maximum dose: 400 mg IV per day
for 45-49 kg weight 45 mg orally once a day
for 50-59 kg weight 55 mg orally once a day
for 60-71 kg weight 65 mg orally once a day
for 72-84 kg weight 80 mg orally once a day
for 85-96 kg weight 90 mg orally once a day
for 97-110 kg weight 105 mg orally once a day
for 111-125 kg weight 115 mg orally once a day
for 126-136 kg weight 135 mg orally once a day
maximum duration of the treatment is 12 weeks
200 mg IV given initially, followed by 100 mg IV every 12hrs
maximum dose given per day is 400 mg
Meningococcal Meningitis Prophylaxis:
100 mg given orally every 12hrs for about five days
200 mg IV given initially, followed by 100 mg IV every 12hrs
maximum dose given per day is 400 mg
200 mg given initially, followed by 100 mg orally every 12hrs
100 to 200 mg initially followed by 50 mg orally four times a day for an alternative regimen
100 mg orally every 12hrs for five days for urethritis in men
200 mg initially followed by 100 mg orally every 12hrs for at least four days for infections other than urethritis and anorectal infections in men
Dosage Forms & Strengths  Â
Tablet or capsule  Â
50mg  Â
75mg  Â
100mg  Â
Tablet-extended release  Â
45mg   Â
55mg   Â
65mg   Â
80mg   Â
90mg   Â
105mg   Â
135mg   
Age: >12years
Extended-release formulations:
for 45-49 kg weight 45 mg orally once a day
for 50-59 kg weight 55 mg orally once a day
for 60-71 kg weight 65 mg orally once a day
for 72-84 kg weight 80 mg orally once a day
for 85-96 kg weight 90 mg orally once a day
for 97-110 kg weight 105 mg orally once a day
for 111-125 kg weight 115 mg orally once a day
for 126-136 kg weight 135 mg orally once a day
maximum duration of treatment is 12 weeks
For > 8 years:
4 mg per kg given orally or IV initially followed by 2 mg per kg orally or IV every 12hrs
Maximum dose 200 mg per dose initially followed by 200 mg per day
When both drugs are combined, there may be an increased intracranial pressure  
When both drugs are combined, there may be an increased intracranial pressure  
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
aluminum hydroxide/magnesium carbonateÂ
may decrease the serum concentration of antacids
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
When both drugs are combined, there may be a decrease in levels of minocycline by inhibition of GI absorption  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decrease in levels of minocycline by inhibition of GI absorption 
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption  
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption  
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption  
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption  
bismuth subsalicylate reduces the levels of minocycline by inhibiting gastrointestinal absorption
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with minocycline it decreases the effects of action of drug by antagonism effect
amoxicillin and clavulanate potassium
when amoxicillin combines with minocycline it decreases the effects of action of drug by antagonism effect
omeprazole amoxicillin and clarithromycin
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
may diminish the absorption of magnesium salts
aluminum hydroxide/magnesium hydroxideÂ
may diminish the absorption of Antacids
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be a decreased effect of conjugated estrogens by altering intestinal flora  
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
They may diminish the absorption when combined with bile acid sequestrants
They may diminish the absorption when combined with bile acid sequestrants
trimagnesium citrate anhydrousÂ
The presence of trimagnesium citrate anhydrous inhibits the gastrointestinal absorption of minocycline, resulting in reduced levels
it may diminish the excretion rate when combined with tetracyclines, resulting in an enhanced serum level
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
sodium picosulfate, citric acid, and magnesium oxide
may diminish the effect of each other when combined
may decrease the therapeutic effect when combined with penicillins
amoxicillin and clavulanate potassium
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
piperacillin decreases the effectiveness of minocycline by antagonism.
When bacampicillin combines with minocycline, the effect and action of bacampicillin decreases.
When penicillin G benzathine combines with minocycline, the action and effectiveness of penicillin G benzathine decreases.
when both drugs are combined, there may be a reduced effect of ceftriaxone by pharmacodynamic antagonism  
The interaction may depress the therapeutic efficacy of tetracyclines
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the toxic effect of anticholinergic agents
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may increase the CNS depressant effect of CNS depressants
may increase the hypoglycemic effect of sulfonylureas
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the CNS depressant effect of CNS Depressants
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may diminish the absorption of magnesium salts
may diminish the absorption when combined with tetracyclines
may have a decrease in excretion when combined with minocycline
When both drugs are combined, there may be an increased effect of antithrombin alfa  
When both drugs are combined, there may be an increased effect of antithrombin III
Tetracyclines work with cations to coordinate with OmpF and OmpC porins to enter bacterial cells.Â
Tetracyclines can enter the periplasm as a result, where they separate and the lipophilic tetracycline diffuses into the bacterial cytoplasm.Â
Tetracyclines decrease protein synthesis by blocking the binding of aminoacyl-tRNA to the 30S ribosome.Â
Adverse drug reactions:  Â
Frequency Not Defined  Â
Anaphylaxis  Â
Angioneurotic edema  Â
Eosinophilia  Â
Pneumonitis  Â
Nephritis  Â
Myocarditis  Â
Swelling of the face  Â
Lymphadenopathy  Â
Angioedema  Â
Alopecia  Â
Erythema nodosum  Â
Erythematous rash  Â
Exfoliative dermatitis  Â
Pruritus  Â
Toxic epidermal necrolysis  Â
Urticaria  Â
Dizziness  Â
Fever  Â
Fatigue  Â
Somnolence  Â
Angioedema  Â
Thyroid dysfunction  Â
Thyroid discoloration  Â
Thyroid cancer  Â
Vulvovaginitis  Â
Pericarditis  Â
Myocarditis  Â
Vasculitis  Â
Hemolytic anemia  Â
Neutropenia  Â
Thrombocytopenia  Â
Pancytopenia  Â
Hepatic cholestasis  Â
Hepatitis  Â
Hyperbilirubinemia  Â
Jaundice  Â
CNS effects  Â
Clostridium difficile diarrhea
None
Contraindication:Â
HypersensitivityÂ
Caution:Â
Liver ToxicityÂ
Central Nervous System (CNS) EffectsÂ
PhotosensitivityÂ
Intracranial HypertensionÂ
Pregnancy warnings:   Â
Breastfeeding warnings:Â
Pregnancy Categories:     Â
Minocycline is a tetracycline antibiotic that inhibits protein synthesis by attaching itself to the bacterial 30S ribosomal subunit.Â
Patients should get counselling on the dangers of pseudotumor cerebri, central nervous system side effects, pseudomembranous colitis, and tooth and bone growth.Â
Avoid rapid intravenous infusion in IV administration and infuse over one hour.Â
Daily dose should not be more than 400 mg.Â
It is administered through oral route in form of tablet and capsule.Â
It should be taken with or without food.Â
Swallow tablets whole at time and avoid chewing or crush.Â
Patient Information Leaflet Â
Generic Name: minocycline (Rx) Â
Pronounced: min· o· cy· clineÂ
Why do we use minocycline?Â
In people with periodontitis, subgingival microspheres are recommended as an adjuvant treatment to decrease pocket depth.Â
Oral and topical minocycline forms are used to treat inflammatory lesions of acne vulgaris.Â
Minocycline oral and intravenous formulations are indicated to treat infections of susceptible microorganisms.Â